Advances in chronic viral hepatitis-2005

[Guest guest]

Advances in chronic viral hepatitis.

Current Opinion in Infectious Diseases. 18(5):400-406, October 2005.

Hui, Yui; Sung, ph Jao-Yiu

Abstract:

Purpose of review: Chronic liver disease due to hepatitis B virus or

hepatitis C virus infection results in cirrhosis and hepatocellular

carcinoma. Successful eradication or suppression of viral replication may

lead to clinical improvement and better prognosis. Important discoveries

have been made in recent years on the management of these diseases. This

article aims at reviewing important publications of the past year that

contribute to better understanding and treatment of chronic viral hepatitis.

Recent findings: The effect of virus genotype on the natural history

continued to be an important topic of research. Landmark studies on the use

of pegylated interferon in chronic hepatitis B and benefit of antiviral

treatment in patients with advanced fibrosis or cirrhosis have been

published. New antiviral agents were evaluated with encouraging results. In

chronic hepatitis C, several treatment trials using pegylated interferon on

HIV-coinfected patients have been published. Treatment in specific groups of

patients, including those with normal alanine transaminase or

posttransplantation recurrence, has also been investigated.

Summary: Major progress has been made in the treatment of chronic hepatitis

B and pegylated interferon is likely to become one of the first-line

therapeutic options in the near future. Combined pegylated interferon and

ribavirin will be the standard treatment regimen for hepatitis C and HIV

coinfection. Future challenges include treatment of hepatitis B and HIV

coinfection and discovery of more potent antiviral agents.

[Guest guest]

Advances in chronic viral hepatitis.

Current Opinion in Infectious Diseases. 18(5):400-406, October 2005.

Hui, Yui; Sung, ph Jao-Yiu

Abstract:

Purpose of review: Chronic liver disease due to hepatitis B virus or

hepatitis C virus infection results in cirrhosis and hepatocellular

carcinoma. Successful eradication or suppression of viral replication may

lead to clinical improvement and better prognosis. Important discoveries

have been made in recent years on the management of these diseases. This

article aims at reviewing important publications of the past year that

contribute to better understanding and treatment of chronic viral hepatitis.

Recent findings: The effect of virus genotype on the natural history

continued to be an important topic of research. Landmark studies on the use

of pegylated interferon in chronic hepatitis B and benefit of antiviral

treatment in patients with advanced fibrosis or cirrhosis have been

published. New antiviral agents were evaluated with encouraging results. In

chronic hepatitis C, several treatment trials using pegylated interferon on

HIV-coinfected patients have been published. Treatment in specific groups of

patients, including those with normal alanine transaminase or

posttransplantation recurrence, has also been investigated.

Summary: Major progress has been made in the treatment of chronic hepatitis

B and pegylated interferon is likely to become one of the first-line

therapeutic options in the near future. Combined pegylated interferon and

ribavirin will be the standard treatment regimen for hepatitis C and HIV

coinfection. Future challenges include treatment of hepatitis B and HIV

coinfection and discovery of more potent antiviral agents.

[Guest guest]

Advances in chronic viral hepatitis.

Current Opinion in Infectious Diseases. 18(5):400-406, October 2005.

Hui, Yui; Sung, ph Jao-Yiu

Abstract:

Purpose of review: Chronic liver disease due to hepatitis B virus or

hepatitis C virus infection results in cirrhosis and hepatocellular

carcinoma. Successful eradication or suppression of viral replication may

lead to clinical improvement and better prognosis. Important discoveries

have been made in recent years on the management of these diseases. This

article aims at reviewing important publications of the past year that

contribute to better understanding and treatment of chronic viral hepatitis.

Recent findings: The effect of virus genotype on the natural history

continued to be an important topic of research. Landmark studies on the use

of pegylated interferon in chronic hepatitis B and benefit of antiviral

treatment in patients with advanced fibrosis or cirrhosis have been

published. New antiviral agents were evaluated with encouraging results. In

chronic hepatitis C, several treatment trials using pegylated interferon on

HIV-coinfected patients have been published. Treatment in specific groups of

patients, including those with normal alanine transaminase or

posttransplantation recurrence, has also been investigated.

Summary: Major progress has been made in the treatment of chronic hepatitis

B and pegylated interferon is likely to become one of the first-line

therapeutic options in the near future. Combined pegylated interferon and

ribavirin will be the standard treatment regimen for hepatitis C and HIV

coinfection. Future challenges include treatment of hepatitis B and HIV

coinfection and discovery of more potent antiviral agents.

[Guest guest]

Advances in chronic viral hepatitis.

Current Opinion in Infectious Diseases. 18(5):400-406, October 2005.

Hui, Yui; Sung, ph Jao-Yiu

Abstract:

Purpose of review: Chronic liver disease due to hepatitis B virus or

hepatitis C virus infection results in cirrhosis and hepatocellular

carcinoma. Successful eradication or suppression of viral replication may

lead to clinical improvement and better prognosis. Important discoveries

have been made in recent years on the management of these diseases. This

article aims at reviewing important publications of the past year that

contribute to better understanding and treatment of chronic viral hepatitis.

Recent findings: The effect of virus genotype on the natural history

continued to be an important topic of research. Landmark studies on the use

of pegylated interferon in chronic hepatitis B and benefit of antiviral

treatment in patients with advanced fibrosis or cirrhosis have been

published. New antiviral agents were evaluated with encouraging results. In

chronic hepatitis C, several treatment trials using pegylated interferon on

HIV-coinfected patients have been published. Treatment in specific groups of

patients, including those with normal alanine transaminase or

posttransplantation recurrence, has also been investigated.

Summary: Major progress has been made in the treatment of chronic hepatitis

B and pegylated interferon is likely to become one of the first-line

therapeutic options in the near future. Combined pegylated interferon and

ribavirin will be the standard treatment regimen for hepatitis C and HIV

coinfection. Future challenges include treatment of hepatitis B and HIV

coinfection and discovery of more potent antiviral agents.